Dr. Esteva on Therapeutic Developments in HER2+ Breast Cancer

Video

In Partnership With:

Francisco Javier Esteva, MD, PhD, discusses therapeutic developments for patients with HER2-positive breast cancer.

Francisco Javier Esteva, MD, PhD, chief, Breast Medical Oncology, Northwell Health Cancer Institute, discusses therapeutic developments for patients with HER2-positive breast cancer.

Historically, patients with HER2-positive breast cancer have poor prognoses, according to Esteva. With the development of drugs such as trastuzumab (Herceptin), pertuzumab (Perjeta), neratinib (Nerlynx), and ado-trastuzumab emtansine (T-DM1; Kadcyla), these patients now have significantly improved outcomes. However, it is important to understand how to sequence and combine these agents to derive the most benefit, Esteva says.

Incorporating neoadjuvant therapy into the treatment plan is important for patients with high-risk, early-stage breast cancer, Esteva explains. Once patients who do not achieve a pathologic complete response to this approach are identified, additional therapies can be used to improve outcomes, Esteva concludes. 

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD